{
    "abstract": "Inflammation plays a role in ST-segment elevation myocardial infarction (STEMI), especially in reperfusion injury (RI). Colchicine, an anti-inflammatory drug, can suppress inflammation during RI. We assessed the effectiveness of administering colchicine to STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in suppressing RI events.\nThis study was a randomized, double-blind, placebo-controlled clinical trial conducted in a multicenter manner at two hospitals in Jakarta with IKPP facilities from December 2022 to April 2023. STEMI patients that underwent PPCI received 2 mg of colchicine as a loading dose and a maintenance dose of 0.5 mg every 12 hours for two days or amylum at a similar dose. Patients were observed for RI events (low-flow thrombolysis in myocardial infarction (0-2) during angiography procedure, reperfusion arrhythmia, cardiogenic shock, or persistent chest pain).\nSeventy-seven STEMI patients with a mean age of 55.2 \u00b1 9.9 years underwent PPCI. Of these patients, 37 received colchicine, and 40 received a placebo. Most subjects were male (77.5%), suffered three-vessel disease (44.15%), and occlusion in left anterior descending coronary artery (53.24%). Colchicine was found to fail to reduce the incidence of ischemia-RI (51.5% vs. 42.4%; p = 0.437). Analysis of comorbidities (hypertension, chronic kidney disease, diabetes mellitus, and obesity) and angiography results (vessel disease, lesion diameter, and culprit artery) failed to demonstrate a statistical difference in RI. Side effects were similar in the colchicine and placebo groups (21.6% vs. 15%).\nColchicine administration in STEMI patients undergoing PPCI failed to reduce RI.",
    "authors": [
        {
            "affiliation": "1. Doctoral Program in Medical Sciences, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia. 2. Division of Cardiology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.. drbirrykarim@yahoo.co.id.",
            "firstname": "Birry",
            "initials": "B",
            "lastname": "Karim"
        },
        {
            "affiliation": null,
            "firstname": "Idrus",
            "initials": "I",
            "lastname": "Alwi"
        },
        {
            "affiliation": null,
            "firstname": "Mohammad",
            "initials": "M",
            "lastname": "Yamin"
        },
        {
            "affiliation": null,
            "firstname": "Merci Monica",
            "initials": "MM",
            "lastname": "Pasaribu"
        },
        {
            "affiliation": null,
            "firstname": "Kuntjoro",
            "initials": "K",
            "lastname": "Harimurti"
        },
        {
            "affiliation": null,
            "firstname": "Nafrialdi",
            "initials": "N",
            "lastname": "Nafrialdi"
        },
        {
            "affiliation": null,
            "firstname": "Taufik",
            "initials": "T",
            "lastname": "Indrajaya"
        },
        {
            "affiliation": null,
            "firstname": "Rivaldo",
            "initials": "R",
            "lastname": "Rivaldo"
        }
    ],
    "conclusions": "Colchicine administration in STEMI patients undergoing PPCI failed to reduce RI.",
    "copyrights": null,
    "doi": null,
    "journal": "Acta medica Indonesiana",
    "keywords": [
        "Colchicine",
        "PPCI",
        "STEMI",
        "inflammation",
        "reperfusion injury"
    ],
    "methods": null,
    "publication_date": "2025-04-23",
    "pubmed_id": "40263680",
    "results": "Seventy-seven STEMI patients with a mean age of 55.2 \u00b1 9.9 years underwent PPCI. Of these patients, 37 received colchicine, and 40 received a placebo. Most subjects were male (77.5%), suffered three-vessel disease (44.15%), and occlusion in left anterior descending coronary artery (53.24%). Colchicine was found to fail to reduce the incidence of ischemia-RI (51.5% vs. 42.4%; p = 0.437). Analysis of comorbidities (hypertension, chronic kidney disease, diabetes mellitus, and obesity) and angiography results (vessel disease, lesion diameter, and culprit artery) failed to demonstrate a statistical difference in RI. Side effects were similar in the colchicine and placebo groups (21.6% vs. 15%).",
    "title": "Role of Colchicine in Reducing Reperfusion Injury in STEMI Patients Who Undergo Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial.",
    "xml": "<Element 'PubmedArticle' at 0x788503cd5300>"
}